Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,559Revenue (TTM) $M160Net Margin (%)-44.6Altman Z-Score1.4
Enterprise Value $M1,550EPS (TTM) $-0.6Operating Margin %-34.5Piotroski F-Score4
P/E(ttm)--Beneish M-Score-2.3Pre-tax Margin (%)-43.6Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %1.4Quick Ratio4.9Cash flow > EarningsY
Price/Sales9.65-y EBITDA Growth Rate %-4.8Current Ratio5.2Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-29.0Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-348.9Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M129ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with HALO

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

HALO is held by these investors:



HALO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Stelzer LaurieCFO 2015-08-20Buy10,000$17.24-30.16view
Stelzer LaurieCFO 2015-08-20Buy10,000$17.24-30.16view
Kelley Kenneth JDirector 2015-06-18Sell20,000$21-42.67view
Kelley Kenneth JDirector 2015-03-05Sell40,000$15.33-21.46view
RAMSAY DAVID AVP and CFO 2014-09-16Buy25,000$8.935.28view
Torley HelenPresident and CEO 2014-09-16Buy50,000$8.9234.98view
PATTON JOHN STUARTDirector 2014-08-19Sell75,000$9.9620.88view
Engler RobertDirector 2014-08-14Sell35,000$9.9620.88view
Engler RobertDirector 2014-05-15Sell126,700$7.5659.26view
PATTON JOHN STUARTDirector 2013-09-16Sell75,000$9.1331.87view

Quarterly/Annual Reports about HALO:

News about HALO:

Articles On GuruFocus.com
Abbvie Ends Development Program With Halozyme Nov 21 2016 
First Eagle Fund of America 3rd Quarter Commentary Oct 28 2016 
First Eagle Overseas Fund Q2 Commentary Aug 03 2015 
Insider Buys at Halozyme Look to Improve Stock Outlook Sep 18 2014 
Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Aug 06 2010 
Halozyme Therapeutics Inc. Reports Operating Results (10-Q) May 07 2010 
Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Nov 06 2009 
Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Aug 07 2009 

More From Other Websites
Halozyme Therapeutics To Present At Upcoming Healthcare Conferences Feb 23 2017
MabVax Therapeutics Studies Lead Investigational Drug MVT-5873 with Halozyme PEGPH20 Feb 13 2017
Halozyme To Host Fourth Quarter 2016 Financial Results Conference Call Feb 01 2017
Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US :... Jan 27 2017
ETFs with exposure to Halozyme Therapeutics, Inc. : January 17, 2017 Jan 17 2017
Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US :... Jan 16 2017
Halozyme Estimates 2017 Revenue of $115M to $130M Jan 11 2017
Why trader is selling Halozyme calls Jan 11 2017
HALOZYME THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 10 2017
Halozyme Therapeutics (HALO) in Focus: Stock Up 6.4% Jan 10 2017
HALOZYME THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 09 2017
Halozyme Provides Program Updates, 2017 Financial Guidance At 35th Annual JP Morgan Healthcare... Jan 09 2017
Can the Rally in Halozyme (HALO) Shares Continue? Jan 09 2017
Biotech Industry Off to a Strong Start in 2017 Latest Reports on Halozyme Therapeutics and Geron Jan 09 2017
ETFs with exposure to Halozyme Therapeutics, Inc. : January 6, 2017 Jan 06 2017
Company News for January 06, 2017 Jan 06 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)